Correction to: The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart.

Journal

Cardiovascular drugs and therapy
ISSN: 1573-7241
Titre abrégé: Cardiovasc Drugs Ther
Pays: United States
ID NLM: 8712220

Informations de publication

Date de publication:
Apr 2020
Historique:
pubmed: 18 2 2020
medline: 18 2 2020
entrez: 17 2 2020
Statut: ppublish

Résumé

The article "The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart".

Identifiants

DOI: 10.1007/s10557-019-06929-2 PMID: 32062792 PMC: PMC7645541
pubmed: 32062792
doi: 10.1007/s10557-019-06929-2
pii: 10.1007/s10557-019-06929-2
pmc: PMC7645541
doi:

Types de publication

Published Erratum

Langues

eng

Sous-ensembles de citation

IM

Pagination

223

Subventions

Organisme : Wellcome Trust
ID : 110158/Z/15/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U105663142
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00015/3
Pays : United Kingdom

Commentaires et corrections

Type : ErratumFor

Auteurs

Mitchel Tate (M)

Heart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Department of Diabetes, Monash University, Melbourne, VIC, Australia.

Gavin C Higgins (GC)

Department of Diabetes, Monash University, Melbourne, VIC, Australia.
JDRF Danielle AlbertiMemorial Centre for Diabetic Complications, Diabetic Complications Division,, Baker Heart and Diabetes Institute, Melbourne, Australia.

Miles J De Blasio (MJ)

Heart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.

Runa Lindblom (R)

Department of Diabetes, Monash University, Melbourne, VIC, Australia.
JDRF Danielle AlbertiMemorial Centre for Diabetic Complications, Diabetic Complications Division,, Baker Heart and Diabetes Institute, Melbourne, Australia.

Darnel Prakoso (D)

Heart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.

Minh Deo (M)

Heart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.

Helen Kiriazis (H)

Experimental Cardiology, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.

Min Park (M)

Department of Medicine, University of Cambridge, Cambridge, Biomedical Campus, Cambridge, UK.

Carlos D Baeza-Garza (CD)

Department of Medicine, University of Cambridge, Cambridge, Biomedical Campus, Cambridge, UK.

Stuart T Caldwell (ST)

WestCHEM School of Chemistry, University of Glasgow, G12 18QQ, Glasgow, UK.

Richard C Hartley (RC)

WestCHEM School of Chemistry, University of Glasgow, G12 18QQ, Glasgow, UK.

Thomas Krieg (T)

Department of Medicine, University of Cambridge, Cambridge, Biomedical Campus, Cambridge, UK.

Michael P Murphy (MP)

Department of Medicine, University of Cambridge, Cambridge, Biomedical Campus, Cambridge, UK.
MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0XY, UK.

Melinda T Coughlan (MT)

Department of Diabetes, Monash University, Melbourne, VIC, Australia.
JDRF Danielle AlbertiMemorial Centre for Diabetic Complications, Diabetic Complications Division,, Baker Heart and Diabetes Institute, Melbourne, Australia.

Rebecca H Ritchie (RH)

Heart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. Rebecca.Ritchie@baker.edu.au.
Department of Diabetes, Monash University, Melbourne, VIC, Australia. Rebecca.Ritchie@baker.edu.au.

Classifications MeSH